These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 6808791)

  • 41. Protective properties and haemagglutinins in serum from humans and in serum from mice injected with a new polyvalent Pseudomonas vaccine.
    Jones RJ; Roe EA
    Br J Exp Pathol; 1975 Feb; 56(1):34-43. PubMed ID: 812544
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Investigations on the efficacy of monovalent Pseudomonas aeruginosa vaccine for oral administration in Pseudomonas aeruginosa experimental infection.
    Meitert E; Sima F; Savulian C; Petrovici M; Chersulick E; Costache G
    Arch Roum Pathol Exp Microbiol; 1989; 48(3):237-51. PubMed ID: 2519634
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Immunological study of glycolipoprotein isolated from extracellular slime of different Pseudomonas aeruginosa serogroups.
    Stanislavsky ES; Kholodkova EV; Youshkova NA; Yourokova IB; Zhvanetskaya MI
    Acta Microbiol Hung; 1986; 33(1):55-67. PubMed ID: 3092559
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Outer membrane protein F (porin) preparation of Pseudomonas aeruginosa as a protective vaccine against heterologous immunotype strains in a burned mouse model.
    Matthews-Greer JM; Gilleland HE
    J Infect Dis; 1987 Jun; 155(6):1282-91. PubMed ID: 3033095
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Serologic and protective cross-reactivity of antisera to Pseudomonas aeruginosa extracellular slime glycolipoprotein.
    Yushkova NA; Kholodkova EV; Korobova TS; Stanislavsky ES
    Acta Microbiol Hung; 1986; 33(2):147-56. PubMed ID: 3101393
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Active and passive immunization strategies for Pseudomonas aeruginosa pneumonia.
    Pennington JE; Pier GB; Sadoff JC; Small GJ
    Rev Infect Dis; 1986; 8 Suppl 4():S426-33. PubMed ID: 2944209
    [TBL] [Abstract][Full Text] [Related]  

  • 47. [Evaluation of properties of Pseudomonas aeruginosa recombinant outer membrane protein F (OprF)].
    Zlygostev SA; Gataullin AG; Kaloshin AA; Mikhaĭlova NA; Zverev VV
    Zh Mikrobiol Epidemiol Immunobiol; 2006; (7):43-7. PubMed ID: 17297879
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Protective effect of an outer membrane vaccine against Pseudomonas aeruginosa infection.
    von Specht BU; Strigl G; Ehret W; Brendel W
    Infection; 1987; 15(5):408-12. PubMed ID: 3121520
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Comparative study of the antibody concentration and protective activity against Pseudomonas aeruginosa of gamma-globulin and IgM-enriched immunoglobulin preparations].
    Kiseleva IA; Kandiurina VG; Timofeeva GV
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Apr; (4):68-71. PubMed ID: 2424197
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Immunization with Pseudomonas aeruginosa outer membrane vesicles stimulates protective immunity in mice.
    Zhang X; Yang F; Zou J; Wu W; Jing H; Gou Q; Li H; Gu J; Zou Q; Zhang J
    Vaccine; 2018 Feb; 36(8):1047-1054. PubMed ID: 29406241
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Killed but metabolically active Pseudomonas aeruginosa-based vaccine induces protective humoral- and cell-mediated immunity against Pseudomonas aeruginosa pulmonary infections.
    Meynet E; Laurin D; Lenormand JL; Camara B; Toussaint B; Le Gouëllec A
    Vaccine; 2018 Mar; 36(14):1893-1900. PubMed ID: 29506924
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Immunological evaluation of an alginate-based conjugate as a vaccine candidate against Pseudomonas aeruginosa.
    Farjah A; Owlia P; Siadat SD; Mousavi SF; Ardestani MS; Mohammadpour HK
    APMIS; 2015 Feb; 123(2):175-83. PubMed ID: 25470757
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Evaluation of the immune responses following co-administration of PilQ and type b-flagellin from Pseudomonas aeruginosa in the burn mouse model.
    Bakht Azad S; Nikokar I; Faezi S; Rasooly S; Mahdavi M
    Microb Pathog; 2018 Oct; 123():426-432. PubMed ID: 30075242
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Active and passive immunization with Pseudomonas aeruginosa ribosomal vaccines and antisera in the burned rat model.
    Lieberman MM; Walker HL; Ayala E; Chapa I
    J Surg Res; 1986 Feb; 40(2):138-44. PubMed ID: 3080639
    [TBL] [Abstract][Full Text] [Related]  

  • 55. A trivalent vaccine consisting of "flagellin A+B and pilin" protects against Pseudomonas aeruginosa infection in a murine burn model.
    Hashemi FB; Behrouz B; Irajian G; Laghaei P; Korpi F; Fatemi MJ
    Microb Pathog; 2020 Jan; 138():103697. PubMed ID: 31465785
    [TBL] [Abstract][Full Text] [Related]  

  • 56. New possibility for providing protection against urinary tract infection caused by Pseudomonas aeruginosa by non-adjuvanted flagellin 'b' induced immunity.
    Sabharwal N; Chhibber S; Harjai K
    Immunol Lett; 2014 Dec; 162(2 Pt B):229-38. PubMed ID: 25455605
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Protective efficacy of recombinant exotoxin A--flagellin fusion protein against Pseudomonas aeruginosa infection.
    Farajnia S; Peerayeh SN; Tanomand A; Majidi J; Goudarzi G; Naghili B; Rahbarnia L
    Can J Microbiol; 2015 Jan; 61(1):60-4. PubMed ID: 25496361
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Effect of common protective antigen vaccination to protect mink from challenge exposure with Pseudomonas aeruginosa.
    Shimizu T; Homma JY; Abe C; Tanamoto T; Aoyama Y; Yanagawa R; Fujimoto Y; Noda H; Takashima I; Honda E; Minamide S
    Am J Vet Res; 1976 Dec; 37(12):1441-4. PubMed ID: 826199
    [TBL] [Abstract][Full Text] [Related]  

  • 59. A polyvalent human gamma-globulin immune to Pseudomonas aeruginosa: passive protection of mice against lethal infection.
    Fisher MW
    J Infect Dis; 1977 Aug; 136 Suppl():S181-5. PubMed ID: 70492
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Establishment of stable cell lines producing anti-Pseudomonas aeruginosa monoclonal antibodies and their protective effects for the infection in mice.
    O'Oka H; Chonan E; Mizutani K; Fukuda T; Kuroiwa Y; Ono Y; Shigeta S
    Microbiol Immunol; 1992; 36(12):1305-16. PubMed ID: 1287405
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.